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??????????：Increased severity of asthma is contributed by airway tissue remodeling, which may be as-
sociated with chronic allergic inflammation. A recent study revealed the potential capacity of repeated bron-
choconstriction, e.g. induced by a muscarine agonist, methacholine（Mch）challenge, to involve in airway re-
modeling, even though allergic inflammation is not implicated. We have evaluated the influence of repeated 
bronchoconstriction induced by Mch inhalation on airway remodeling in a murine model of asthma and have 
examined its machanisms.
???????：Mice were immunized with ovalbumin（OVA）, and consequently, challenged by either daily 
OVA inhalation（the OVA group；a model of asthma with allergic inflammation）or daily Mch inhalation（the 
Mch group；a model of asthma without allergic inflammation）. Lung tissues were obtained and were evalu-
ated histologically after 5, 10, and 15 consecutive inhalation challenges of both OVA and Mch.
???????：Eosinophilia in the airway observed only on the OVA group. Subepithelial collagen-band thick-
ness increased also in the OVA group（p＜0.01）after 15 challenges, but not in the Mch group. Significant 
increase in thickness of airway smooth muscle layer and the number of goblet cells were revealed in both 
the OVA and Mch group after 10（p＜0.05 and p＜0.01, p＜0.01 and p＜0.05, respectively, for the compari-
son of the two challenge groups with the control group）and 15 challenges（p＜0.05 and p＜0.01, both p＜
0.01 , respectively, for the comparison with control）, further, all these measurements were greater in the 
OVA group than in the Mch group after both 10 and 15 challenges（both p＜0.05 and p＜0.01, respective-
ly）. An increase in mast cell counts within the airway wall was shown in the OVA group after 10 challenges
（p＜0.01 compared with control）, not in the Mch group at all. Epithelia expression of transforming growth 
factor b  （TGF-b）increased in both challenge groups after 15 challenges（both p＜0.05 compared with 
control）, and was higher than in Mch（p＜0.05）.
??????????：Repeated Mch inhalation may induce airway remodeling, while comparatively mild, poten-
tially resulting in progressive severity of asthma. The results implicate that the potential risk associated 
with Mch challenge should be considered.
???? ????： airway remodeling, animal model, 
asthma, eosinophils, methacholine
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????????????
Asthma is a chronic inflammatory disease of the air-
ways, characterized by airway hyperresponsiveness
（AHR）and reversible airflow limitation caused by 
bronchoconstriction and is associated with proliferative 
structural changes of the airway walls, referred to as 
airway remodeling1〜4）. Whereas, these structural 
changes contribute to the AHR and the limitation of 
reversible airflow obstruction, and consequently lead to 
an increase in severity of the disease in asthmatic pa-
tients. Airway remodeling represents structural chang-
es of the airways, such as subepithelial fibrosis, hyper-
trophy and hyperplasia of airway smooth muscle mass, 
and goblet cell proliferation, and has been considered a 
consequence of eosinophilic inflammation, i.e. allergic 
inflammation, in the airways, induced by inhaled-aller-
gen challenge in atopic asthma5）.
Recently a study has demonstrated that repeated in-
halation of methacholine（Mch）, a muscarine agonist, 
which causes bronchoconstriction without eosinophilic 
inflammation, possibly induce the similar structural 
changes of the airways6）. To develop our understand-
ing of the pathophysiology of the airway remodeling in 
asthma should be most effective measures for investi-
gating potential targets for therapeutic intervention.
Accordingly, we examined the influence of repeated 
inhalation of Mch on pathology and pathogenesis of the 
airway disease by means of employing a mouse model 
of asthma. The results have clarified whether repeated 
Mch inhalation, namely recurrent bronchoconstriction 
without non-allergic inflammation, can lead the similar 
structural modification of the airways, i.e. airway re-
modeling, in asthma, and therefore discussed the po-
tential mechanisms of forming that airway remodeling.
????????????????????
Animals and Study design
Mouse models of asthma were established from 
OVA-sensitized mice according to methods reported 
previously with some modifications7〜10）. Male BALB/c 
mice（Clea, Japan）of 8 weeks of age were immunized 
by intraperitoneal（IP）injected with 8 mg ovalbumin
（OVA；Sigma-Aldrich, St. Louis, MO）in 4 mg Al
（OH）3 gel（alum；Sigma-Aldrich）on days 0 and 7
（Figure 1）, and was consecutively challenged by 20-
min daily inhalation of 1 mg/ml OVA for 5, 10, or 15 
consecutive days（OVA group）. To induce bronchocon-
striction, as mechanical stress alone, without allergic 
inflammation, mice were challenged by 15-min daily 
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????????　Protocols for sensitization and challenge
Closed arrows indicate inhalation（IH）, gray arrows indicate intraperitoneal 
administration, and open arrows indicate sacrifice. N＝21 for each group and n＝7 
for each measurement.
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inhalation of acetyl-b-methylcholine chloride, metha-
choline（Sigma-Aldrich）（Mch group）to establish an 
inflammation-independent mechanical stress asthma 
model. The control group received intraperitoneal sa-
line injections instead of OVA-alum on days 0 and 7, 
and inhaled saline daily for 20 min for 5, 10, or 15 con-
secutive days. For inhalation, mice were placed in 
sealed chambers and drugs were aerosolized by an ul-
trasonic nebulizer（Omron, Kyoto, Japan）. On days 19, 
24, and 29（after 5, 10, and 15 inhalation treatments, 
respectively）, lung tissues were collected for histologi-
cal analyses. The above protocol was approved by the 
Committee of Laboratory Animal Research Center at 
Dokkyo Medical University（#02-261）.
Histological preparation
Lungs were removed, fixed in 4％ paraformaldehyde, 
embedded in paraffin, and sliced into 3-mm thick sec-
tions. Sections were stained histochemically with Han-
sel（Eosinostain, Torii Pharmaceutical, Tokyo, Japan）
Elastica-Masson, and alcian-blue and periodicacid-
Schiff（PAS）for the detection of eosinophils, the colla-
gen band, and goblet cells, respectively, and were 
stained immunohistochemically with the use of anti-
mouse mast cell tryptase mAb（Abcam, Cambridge, 
UK）and with the use of anti-mouse actin and a-
smooth muscle mAb（Sigma-Aldrich）, each of which 
combined with N-Histofine MOUSESTAIN KIT®
（Nichirei, Tokyo, Japan）for the detection of mast cells 
and smooth muscle mass, respectively. To evaluate the 
expression of TGF-b , tissues also were stained with 
anti-mouse TGF-b  mAb（Abcam）, combined with the 
VECTASTAIN Elite ABC Kit®（Vector Laboratories, 
CA）, and N-Histofine Simple Stain DAB solution®
（Nichirei）
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????????　Expansion of the airway collagen band in the OVA group but not in the Mch group
Change in collagen band thickness in OVA-injected/OVA-boosted（OVA group）mice, OVA-
injected/methacholine（Mch）-challenged mice（Mch group）, and saline-injected control group 
mice after 5, 10, or 15 challenges. The allergic inflammation model（OVA group）showed greater 
collagen band thickness after 15 challenges than either the Mch or control groups. ＊＊p＜0.01 and 
＊p＜0.05. Significant differences by number of challenges were observed between 10 and 15 
challenges in the OVA group（p＜0.05）, between 5 and 10 challenges in the Mch group（p＜
0.05）, and between 5 and 15 challenges in the Mch group（p＜0.05）. N＝21 for each group, and n
＝7 for each measurement. Data expressed as mean ± SEM.
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Collagen band thickness, which is a marker of in-
flammatory fibrosis, increased progressively as a fre-
quency of OVA challenge（Fig. 2）. Collagen band 
thickness increased significantly in the OVA group be-
tween 10 and 15 challenges（1.45±0.07 mm vs. 1.78±
0.06 mm, p＜0.05）, while collagen band thickness in 
Mch group increased significantly between the five 
and ten challenge（1.03±0.05 mm vs. 1.27±0.08 mm, p
＜0.05）and between the five and fifteen（p＜0.05）, but 
not between the ten and fifteen（1.27±0.08 mm vs. 
1 .33±0.11 mm）. The collagen band was significantly 
thicker in the OVA group after 15 daily OVA chal-
lenges than in either the Mch group after the same 
number of challenges（p＜0.01）or in the control group
（p＜0.01）. In contrast, the collagen band thickness was 
no greater in the Mch group compared to the control 
group（p＞0.05）. Thus, Mch-induced remodeling was 
Measurement of airway thickness, collagen band thick-
ness, infiltrating cell numbers, and TGF-b  expression
Airway and collagen band thicknesses were estimat-
ed along the main bronchus. The number of goblet 
cells in the main bronchus was also counted during es-
timation of airway and collagen band thicknesses. The 
number of infiltrating eosinophils in the main bronchus 
was estimated by counting Hansel-stained cells and 
expressed per one millimeter square11）. Similarly, the 
number of infiltrating mast cells was estimated by 
counting the number of tryptase-positive cells. The 
expression of TGF-b  in trachea was estimated by inte-
gration of the immunostaining signal.
Statistical Analysis
Statistical analyses were performed using Microsoft 
Excel® or JMP®（for the Wilcoxon signed rank test）. A 
P value＜0.05 was considered significant. Results are 
expressed as mean±standard error of the mean
（SEM）.
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????????　Expansion of the airway smooth muscle layer in both the OVA and Mch group
＊＊p＜0.01 and ＊p＜0.05. Both the OVA and Mch groups exhibited smooth muscle layer expansion 
compared to the control group. Expansion was greater in the OVA mice, indicating more 
substantial remodeling. No significant differences by number of challenges were observed in any of 
the groups. N＝21 for each group and n＝7 for each measurement. Data expressed as mean ± 
SEM.
Airway remodeling by methacholine inhalation
in the OVA group than the Mch and control groups
（both p＜0.01）and greater in the Mch group com-
pared to the control group（p＜0.01 or p＜0.05）. Thus, 
Mch-induced remodeling includes mild goblet cell hy-
perplasia.
Immune cell infiltration
The numbers of eosinophils infiltrated into the air-
way was significantly higher in the OVA group at all 
measurements（Fig. 5；p＜0.01 vs. Mch and control 
groups）, but there was no effect of challenge number. 
In contrast, no significant eosinophil infiltration was ob-
served in the Mch group as cell numbers were no 
higher than in the control group. The numbers of mast 
cells infiltrated into the airway（Fig. 6）was also sig-
nificantly higher in the OVA group compared to the 
Mch group after 5 and 10 challenges（5 challenges：4.0
±1.0 cells vs. 1.3±0.4 cells, p＜0.05；10 challenges：8.7
±0.7 cells vs. 4.5±1.0 cells, p＜0.05）and compared to 
the control group after both 5 and 10 challenges（p＜
not associated with fibrosis.
Airway smooth muscle thickness increased progres-
sively with the number of challenges in both the OVA 
and Mch groups（Fig. 3）, although the differences 
among the three measurements were not significant. 
At all measurements, however, airway smooth muscle 
thickness was greater in the OVA group compared to 
both the Mch group（p＜0.05）and control group（p＜
0.05）. After 10 and 15 challenges, smooth muscle thick-
ness was also greater in the Mch group compared to 
the control group（p＜0.01）. Thus, Mch-induced re-
modeling appears to include smooth muscle hyperpla-
sia and/or hypertrophy.
The OVA group exhibited a significantly higher 
number of goblet cells（Fig. 4）, although these num-
bers did not increase significantly with the number of 
challenges. In contrast, the number of goblet cells did 
increase progressively with the number of challenges 
in the Mch group（five vs. ten p＜0.01）. At all mea-
surements, goblet cell number was significantly greater 
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????????　Goblet cell hyperplasia in both the OVA and Mch group
The OVA group showed substantial goblet cell hyperplasia. The Mch group showed more modest 
goblet cells hyperplasia. ＊＊p＜0.01 and ＊p＜0.05. No significant differences by number of 
challenges were observed in the OVA group, but there were significant differences between 5 
and 10 challenges（p＜0.01）and between 5 and 15 challenges（p＜0.01）in the Mch group. N＝
21 for each group and n＝7 for each measurement. Data expressed as mean±SEM.
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????????　Eosinophilia in the OVA but not Mch group
The OVA group showed substantial eosinophil infiltration into the airway, while the Mch group did not. ＊＊p
＜0.01. No significant differences by number of challenges were observed in any of the three groups. N＝21 
for each group and n＝7 for each measurement. Data expressed as mean±SEM.
????????　Mast cell infiltration
The numbers of mast cells increased in the airway of the OVA group compared to the Mch and control groups 
after 5 and 10 challenges. ＊＊p＜0.01 and ＊p＜0.05. No significant differences by number of challenges were 
observed in the OVA group. However, significant differences were observed in the Mch group（5 vs. 10 
challenges；p＜0.05, 5 vs. 15 challenges；p＜0.01）and in the control group（5 vs. 10 challenges；p＜0.05, 5 vs. 
15 challenges；p＜0.01）. N＝21 for each group and n＝7 for each measurement. Data expressed as mean ± SEM.
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0.01）, but not after 15 challenges（7.7±2.1 cells vs. 5.6
±1.1 cells vs. 3.3±0.5）. Expression of TGF-b（Fig. 7）
was significantly higher in the OVA group compared 
to the control group after 10 challenges（22.7±10.4 vs. 
3 . 7±1 .1 , p＜0 .01）and compared to both the Mch 
group and control groups after 15 challenges（56.4±
17.7 vs. 7.1±0.4 vs. 4.3±0.9；p＜0.05 vs. both）. TGF-
b  expression was significantly higher in the Mch group 
compared to the control group after 15 challenges（p＜
0 .05）. Unlike OVA-associated remodeling, Mch-in-
duced remodeling does not include eosinophilia, but 
does include mild mast cell infiltration and TGF-b  ex-
pression.
??????????
Both the subepithelial collagen band and airway 
smooth muscle layer were expanded significantly by 
OVA immunization and subsequent booster sensitiza-
tion, verifying successful induction of airway remodel-
ing. However, frequent inhalation of the non-inflamma-
tory agent MC also induced airway remodeling, albeit 
more restricted than that induced by OVA. These find-
ings support results from patients with asthma and 
suggest that overuse of Mch may exacerbate asthma 
severity6）.
Airway remodeling induced by Mch may result from 
two pathogenic pathways, bronchoconstriction-depen-
dent stress and Mch-induced inflammation. Airway 
smooth muscles may become hypertrophied by fre-
quent Mch-induced bronchoconstriction even if it were 
without airway inflammation（stress-induced hypertro-
phy）. For example, arterial smooth muscles were hy-
pertrophied and synthesis of matrix components stimu-
lated by mechanical pressure12,13）. Actually, the effects 
of frequent mechanical stress alone have not been con-
sidered in airway, because it is difficult to separate 
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????????　 Substantial overexpression of TGF-b  by the OVA group and more modest overexpression 
by Mch group
The OVA group expressed substantially higher levels of TGF-b  than the control group after 10 and 
15 challenges and higher levels than the Mch group after 15 challenges. The Mch group expressed 
higher levels of TGF-b  than the control group after 15 challenges. ＊＊p＜0.01 and ＊p＜0.05. 
Significant differences by number of challenges were observed between 5 and 10 challenges（p＜
0.05）and between 5 and 15 challenges（p＜0.05）in the OVA group and between 5 and 15 
challenges（p＜0.01）in the Mch group. N＝21 for each group and n＝7 for each measurement. Data 
expressed as mean ± SEM.
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these effects from those of airway inflammation2〜5）. In 
the present study, airway smooth muscles treated with 
Mch were significantly hypertrophied. In contrast to 
the OVA group, however, collagen band thickness was 
not significantly expanded by Mch, indicating that air-
way inflammation induces more uniform remodeling 
than frequent mechanical bronchoconstriction. None-
theless, frequent mechanical bronchoconstriction can 
induce uneven airway remodeling that may impede 
respiration.
These results have two major implications for the 
diagnosis and treatment of asthma. First, examination 
of airway hyperresponsiveness using Mch or acetyl-
choline should be limited to use. Namely the airway 
hyperresponsiveness examination should be performed 
only for the initial diagnosis of asthma. Second, bron-
chodilators like LABA may contribute to inhibit re-
modeling. The US-FDA recommendation against regu-
lar use except by patients not successfully treated by 
ICS is based on the view that inhibition of airway in-
flammation is the most important treatment goal for 
asthma medication, and we agre14）. Nonetheless, regu-
lar use of LABA may lead to prevention airway re-
modeling caused by frequent bronchoconstriction.
The other possible Mch-induced remodeling path-
way is mimic allergic inflammation. In one study, Mch 
increased Ki67-positive cell population in both the epi-
thelium and the submucosa of asthma patients 6）. The 
authors suggested that Mch could damage the airway 
epithelium and that upregulation of the proliferation 
regulator, Ki67 is a reparative response. If Mch does 
cause mimic allergic inflammation, it likely occurs with-
out eosinophil infiltration as neither the aforementioned 
clinical study6）nor our study found a significant in-
crease in tissue eosinophil number. In contrast, we did 
not evaluate the number of Ki67-positive cells. We 
cannot eliminate the possibility of Mch-induced cellular 
damage leading inflammation as no study has yet in-
vestigated Mch toxicity on isolated airway epithelial 
cells. It has also been reported that chronic intermit-
tent mechanical stress from bronchoconstriction can 
increase mucin protein expression and goblet cell pro-
liferation15）, consistent with our observation of in-
creased numbers of alcian-blue PAS-positive cells. The 
other possibility is that Mch or mechanical stress on 
the airway may induce mimic allergic inflammation 
though a pathway not involving activation of eosino-
phils. In such a case, mast cells could be the principal 
mediator cell, because Mch enhanced mast cells infil-
tration and infiltration increased with the number of 
challenges16）. Mast cells express receptors for IL-3, IL-
5, and granulocyte-macrophage-colony stimulating fac-
tor（GM-CSF）, and they regulate allergic airway in-
flammation together with T-cells 17）. Also, mast cells 
activate fibroblasts to produce fibrogenic cytokines 
such as TGF-b 18）, thereby contributing to pulmonary 
fibrosis. Epithelial TGF-b  was increased by Mch in 
both a previous study on asthma patients6）and in our 
study, and again expression increased with Mch chal-
lenge number. Therefore, it appears possible that Mch 
caused mimic allergic inflammation without eosinophil-
ia. However, Mch caused no significant expansion of 
the collagen band. Further studies are required to dis-
tinguish Mch-induced remodeling via inflammation 
from remodeling via mechanical stress.
Eosinophilic inflammation induced by OVA had the 
strongest effect on airway remodeling, but frequent in-
halation of Mch also induced several remodeling re-
sponses without airway eosinophilia. Eosinophilia is im-
portant in the pathogenesis of asthma, but may not be 
essential key factor because mepolizumab, a humanized 
monoclonal antibody against IL-5 that inhibits airway 
eosinophilia, did not improve airway hyperresponsive-
ness19）. Subsequent studies reported conflicting results 
on the efficacy of mepolizumab for asthma treat-
ment20〜25）. A more recent study reported that anti-
IL-5 receptor a mAb, not anti-IL-5 mAb, inhibited air-
way hyperresponsiveness in a mouse asthma model10）. 
Airway smooth muscles express IL-5 receptor-a, and 
IL- 5 contributes to airway remodeling26）. Thus, 
IL-5 may be an important signaling factor for airway 
remodeling, although the expression of IL-5 was not 
measured in our study.
In summary, frequent inhalation of Mch may be a 
risk factor for airway remodeling. Airway remodeling 
induced by Mch may arise from frequent mechanical 
bronchoconstriction or mast cell-dependent, eosino-
phil-independent mimic allergic inflammation. We rec-
ommend that frequent inhalation of Mch should be 
limited to use. This test should be performed for initial 
asthma diagnosis but not for regular treatment moni-
toring.
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